Wednesday, July 20, 2011 11:28:19 AM
BOSTON (MarketWatch) -- Shares of AMAG Pharmaceuticals /quotes/zigman/107237/quotes/nls/amag AMAG -13.95% dropped 14% to $16.46 on Wednesday following news that it plans to merge with Allos Therapeutics /quotes/zigman/81880/quotes/nls/alth ALTH -1.94% in an all-stock deal valued at around $686 million. Following the merger, AMAG shareholders will hold a 61% stake in the new company, while Allos stockholders will have 39%. The combined company will be headquartered in Lexington, Mass., and will be renamed "to reflect its strategic focus," the companies said. The deal is expected to close in the fourth quarter. Shares of Allos were down 1%.
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM